$498 Million is the total value of BVF INC/IL's 29 reported holdings in Q4 2016. The portfolio turnover from Q3 2016 to Q4 2016 was 66.7% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| BPMC | Buy | BLUEPRINT MEDICINES CORP | $91,311,000 | +11.2% | 3,255,280 | +17.7% | 18.35% | +18.6% |
| GLYC | Buy | GLYCOMIMETICS INC | $17,240,000 | -0.6% | 2,826,282 | +16.5% | 3.46% | +6.0% |
| CASC | New | CASCADIAN THERAPEUTICS INC | $13,504,000 | – | 3,133,224 | +100.0% | 2.71% | – |
| INFI | Buy | INFINITY PHARMACEUTICALS INC | $10,612,000 | +32.1% | 7,860,808 | +52.6% | 2.13% | +40.8% |
| ACHN | New | ACHILLION PHARMACEUTICALS INC COM | $10,008,000 | – | 2,423,300 | +100.0% | 2.01% | – |
| FATE | New | FATE THERAPEUTICS INC | $9,436,000 | – | 3,759,398 | +100.0% | 1.90% | – |
| ESPR | Buy | ESPERION THERAPEUTICS INC NE | $8,924,000 | +30.5% | 712,770 | +44.3% | 1.79% | +39.1% |
| ADRO | Buy | ADURO BIOTECH INC | $8,503,000 | +36.5% | 745,886 | +48.8% | 1.71% | +45.5% |
| IMDZ | Buy | IMMUNE DESIGN CORP | $7,261,000 | -20.2% | 1,320,164 | +10.0% | 1.46% | -14.9% |
| GTXI | New | GTX INC DEL | $5,853,000 | – | 1,108,433 | +100.0% | 1.18% | – |
| SNSS | Buy | SUNESIS PHARMACEUTICALS INC | $5,042,000 | +58.0% | 1,392,720 | +90.7% | 1.01% | +68.6% |
| NVLS | Buy | NIVALIS THERAPEUTICS INC | $4,176,000 | -70.0% | 1,864,474 | +9.1% | 0.84% | -68.0% |
| PIRS | Buy | PIERIS PHARMACEUTICALS INC | $2,606,000 | +40.3% | 1,854,768 | +82.4% | 0.52% | +49.7% |
| XOMA | New | XOMA CORP DEL | $1,278,000 | – | 302,800 | +100.0% | 0.26% | – |
| ANTH | New | ANTHERA PHARMACEUTICALS INC | $40,000 | – | 62,292 | +100.0% | 0.01% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2017-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| XENON PHARMACEUTICALS INC | 36 | Q3 2023 | 4.7% |
| PIERIS PHARMACEUTICALS INC | 30 | Q3 2023 | 2.8% |
| CYTOKINETICS INC | 29 | Q4 2020 | 11.8% |
| INFINITY PHARMACEUTICALS INC | 29 | Q2 2023 | 4.3% |
| XOMA CORP DEL | 28 | Q3 2023 | 7.3% |
| ARQULE INC | 27 | Q4 2019 | 4.8% |
| CHEMOCENTRYX INC | 26 | Q3 2019 | 13.8% |
| CYTOMX THERAPEUTICS INC | 26 | Q3 2023 | 5.3% |
| CORVUS PHARMACEUTICALS INC | 26 | Q3 2023 | 2.3% |
| ARRAY BIOPHARMA INC | 25 | Q2 2019 | 14.5% |
View BVF INC/IL's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| 4 | 2024-05-13 |
| 13F-HR | 2024-02-14 |
| 4 | 2024-01-29 |
| 3 | 2024-01-26 |
| 4 | 2024-01-09 |
| 4 | 2023-12-20 |
| 4 | 2023-11-17 |
| 13F-HR | 2023-11-14 |
| 3 | 2023-11-13 |
View BVF INC/IL's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.